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RESULTS

BCL9 promotes the proliferation of BMECs
As it is documented that bone marrow angiogenesis is a positive correlate of disease activity [8] [9] [10] , we evaluated microvascular density in our own collection of bone marrow biopsies from healthy controls, MM patients and subjects with the premalignant condition monoclonal gammopathy of undetermined significance (MGUS), as assessed by immunohistochemistry of the endothelial cell marker CD34. As compared to samples from control individuals, in which there were few and scattered small blood vessels, the size, number and density of blood vessels were increased markedly in bone marrow from subjects with MM and to a lesser extent in samples from MGUS subjects (Fig. 1a) . These results confirm previous observations of increased bone marrow microvascular density in MM patients with advanced disease [8] [9] [10] , and suggest a possible role of BMECs in promoting MM progression.
BCL9, a transcriptional coactivator of β-catenin, has critical roles in the pathogenesis of various human cancers, including MM [13] [14] [15] [16] [17] . We previously showed that stabilized α-helix peptides derived from the HD2 domain of BCL9 (SAH-BCL9), the domain of BCL9 that binds to β-catenin, inactivate native β-catenin-BCL9 complexes and ablate angiogenesis in a mouse xenograft model of MM 17 . This finding prompted us to evaluate BCL9 expression in BMECs by immunohistochemistry. High levels of BCL9 nuclear staining were detected in cells in close physical contact with MM cells in bone marrow biopsies from both healthy controls and individuals with MM ( Fig. 1b and Supplementary Fig. 1a ). Double-immunostaining for BCL9 and CD34 confirmed BCL9 expression in BMECs (Fig. 1b) . Nuclear colocalization of BCL9 and β-catenin in two representative primary BMEC samples from MM subjects, as well as in BMEC-60 (ref. 18 ) and BMEC-1 (ref. 19 ) cells, was confirmed by immunoblotting ( Fig. 1c) and immunofluorescence (Fig. 1d) . Lentiviral knockdown of BCL9 in BMEC-60 and BMEC-1 cells and in primary BMECs from an MM subject (PBMEC-1 cells) using BCL9 shRNA 13 ( Supplementary Fig. 1b ) was associated with decreased Wnt reporter activity ( Fig. 1e ) and cell proliferation (Supplementary Fig. 1c) . Consistent with our previous study 17 , BMEC proliferation was also inhibited by SAH-BCL9 (Fig. 1f) .
BMECs promote the proliferation and survival of MM cells Bone marrow stromal cells were initially thought to be the only cell type with which MM cells interact functionally 20 . However, once bone marrow angiogenesis was recognized as a hallmark of MM progression, it became clear that BMECs contribute to this process 21 . To understand the mechanisms by which BMECs promote MM progression, and to evaluate the possible role of BCL9 in this process, we performed biochemical and functional studies using cocultured cells. Immunoblotting revealed that culturing of either of two MM cell lines, H929 and MM.1S, with BMEC-60 cells activated several signaling pathways known to promote the survival, proliferation and migration of MM cells (Fig. 2a) 22 . Similar results were obtained when MM and BMEC-60 cells were cocultured in separate chambers (Transwell assays) (Fig. 2b) , indicating that a soluble factor (or factors) secreted by BMEC-60 cells is responsible for the observed effects on MM cell signaling. Primary BMECs were as effective as BMEC-60 cells in causing these signaling effects (Fig. 2c) . Coculture with BMEC-60 cells similarly promoted the proliferation of MM.1S cells (Fig. 2d) and MM primary tumor cells ( Fig. 2e) and also elicited drug resistance in MM.1S cells (Fig. 2f) . Primary BMECs were as effective as BMEC-60 cells in promoting the proliferation of MM cells (Fig. 2g) . BCL9 knockdown in BMEC-60 cells was associated with decreased levels of phosphorylated signal transducer and activator of transcription 3 (pSTAT3), phosphorylated protein kinase AKT (pAKT) and phosphorylated ERK (pERK) (Fig. 2h) , as well as reduced proliferation of cocultured MM.1S cells (Fig. 2i) . Results are mean ± s.d. for assays performed in triplicate. Two independent assays were done for e and f. Statistical significance of differences between groups was determined via unpaired Student's t-test. **P < 0.01, ****P < 0.0001. Two independent assays were done for all data for which statistics were calculated. Statistical significance of differences between groups was determined by unpaired Student's t-test. β-cat, β-catenin. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
BMECs promote the migration and proliferation of MM cells As ERK activation has been implicated in cell migration 23 , our finding of enhanced pERK expression in MM cells cultured with BMEC-60 cells prompted us to ask whether this activation was associated with increased cell migration. Conditioned medium from cultures of BMEC-60 cells (Fig. 3a) or primary BMECs (Fig. 3b) , but not from bone marrow-derived stromal HS5 cells (Fig. 3c) , promoted the migration of luciferase-labeled MM.1S (MM.1S-luc) cells. Protease treatment of BMEC-60-derived conditioned medium reduced the migration of MM.1S-luc cells (Fig. 3a) . The migration of MM.1S-luc cells was enhanced more strongly by conditioned medium from primary BMECs than by conditioned medium from primary bone marrow stromal cells (BMSCs) isolated from the same person (Fig. 3c) . The migration of other MM cell lines was also enhanced by conditioned medium derived from HS5 cells and derived from primary BMECs, but not by medium derived from primary BMSCs from the same person ( Supplementary Fig. 1d,e) .
To investigate the role of BMECs in the migration of MM cells in vivo, we used a scaffold-based mouse xenograft system 24 (Fig. 3d) meant to simulate vital human-human heterotypic interactions between MM and bone marrow cells. The system uses three-dimensional bone-like poly-ε-caprolactone scaffolds that can be coated with human bone marrow-derived cells and implanted into the flanks of immunocompromised mice. After luciferase-labeled human MM cells had been injected into a mouse via the tail vein, tumor-cell proliferation within the scaffold was monitored by whole-body imaging. Whereas scaffolds coated with BMEC-60 cells supported the migration and proliferation of MM.1S-luc cells, uncoated scaffolds or scaffolds coated with HS5 cells did not (Fig. 3e-g and Supplementary Fig. 1f ). Migration and proliferation of H929-luc cells were similarly observed in scaffolds coated with primary BMECs, but not in uncoated scaffolds (Supplementary Fig. 1g-i) . Migration and proliferation of primary MM cells in scaffolds coated with BMEC-60 cells were also observed (Supplementary Fig. 2a ), albeit at a lower level and frequency than for MM.1S-luc cells (two in ten scaffolds versus three in three scaffolds). Primary BMECs were more efficient than primary BMSCs isolated from the same individual in promoting the migration and proliferation of MM.1S-luc cells within scaffolds (Fig. 3h-j) .
BCL9 knockdown in BMECs reduces the migration and proliferation of MM cells
To investigate whether BCL9 is needed to promote the migration and proliferation of MM cells, we knocked down BCL9 expression in BMECs (Supplementary Fig. 1b) . Compared to that of cells cultured with control-shRNA-treated BMECs, in vitro migration of MM.1S-luc (Fig. 4a ) and H929 cells (Supplementary Fig. 2b ) was decreased when these cells were cultured with BMEC-60 or BMEC-1 cells that had been transduced with BCL9 shRNAs. In vivo migration and proliferation of . PBMEC-1 and PBMSC-1 cells were from one individual, and PBMEC-2 and PBMSC-2 cells were from another. In h, "1" and "2" indicate that the scaffolds were coated with PBMEC-1 and PBMEC-2 cells, respectively (dark blue outlines), or with PBMSC-1 and PBMEC-2 cells, respectively (light blue outlines). In h, four scaffolds were implanted per mouse, and three mice were used. One representative mouse is shown. Scale bars in j, 50 µm. Statistical analyses of tumor burden were done using factorial analysis in SPSS 13.0. *P < 0.05, **P < 0.01, ****P < 0.0001.
MM.1S-luc cells in scaffolds were also inhibited when the scaffolds were coated with BMEC-60 cells that had been transduced with BCL9 shRNA, but not when the coating cells had been transduced with control shRNA (Fig. 4b-d and Supplementary Fig. 2c,d ). Histological analysis confirmed uniform scaffold coating by either BMEC-60 cells transduced with control shRNA or BMEC-60 cells transduced with BCL9 shRNA, as well as the absence of MM.1S-luc cells in scaffolds coated with BMEC-60 cells transduced with BCL9 shRNA (Fig. 4d) . Similar results were observed for H929-luc cells using scaffolds coated with BMEC-60 cells ( Supplementary Fig. 2e-g ).
Proteomic analysis identifies eCyPA as a signaling factor secreted by BMECs The foregoing results prompted us to perform proteomic analysis to identify signaling molecules secreted by BMECs that can promote the migration and proliferation of MM cells and whose expression is regulated by BCL9. Silver-stained agarose gels showed a decrease in the levels of low-molecular-weight proteins in conditioned medium from BMEC-60 cells transduced with control shRNA compared with that of proteins in conditioned medium from the same cells transduced with BCL9 shRNA (Supplementary Fig. 2h ). These lowmolecular-weight proteins were also not detected in conditioned medium from HS5 cells (Supplementary Fig. 2h ). To identify low-molecular-weight proteins secreted by BMECs, we performed proteomic analysis of the six major bands of <28 kDa, excised from silver-stained gels, in the conditioned medium of BMEC-60 cells transduced with control shRNA and in total conditioned medium from either BMEC-60 cells transduced with control shRNA or two primary BMECs. This analysis provided a large number of candidate proteins that had been previously characterized as secreted proteins with known signaling functions ( Fig. 4e and Supplementary  Tables 1 and 2 ). Among these, we focused on eCyPA and eCyPB 25, 26 as the candidate proteins most likely to promote the migration and proliferation of MM cells. ELISA confirmed the presence of eCyPA and eCyPB in conditioned medium from BMEC-60 cells transduced with control shRNA, as well as reduced levels of these proteins in conditioned medium from BMEC-60 cells transduced with BCL9 shRNA and from HS5 cells (Fig. 4f) . Moreover, primary BMECs secreted much more eCyPA than did primary BMSCs from the same person (Fig. 4g) , and both BMEC-60 cells and primary BMECs secreted much more eCyPA than eCyPB (Fig. 4f,g ). Immunoblotting of BMEC-60 cells transduced with BCL9 shRNA confirmed stable BCL9 knockdown and decreased cellular CyPA and CyPB expression (Supplementary Fig. 2i ), indicating that both CyPA and CyPB, which have overlapping signaling functions 27 , are regulated by BCL9. Immunoblotting of other bone marrow-derived cell samples, including primary BMECs and primary BMSCs from the same person (Fig. 1c and Supplementary Fig. 1d) , as well as immunostaining of bone marrow biopsies from healthy subjects (Fig. 4h and Supplementary  Fig. 3a) , confirmed that most BMECs expressed CyPA, and that CyPB expression was lower than CyPA expression. Immunostaining also showed that bone marrow myeloid cells expressed a large amount of CyPA, but not of CyPB ( Fig. 4h and Supplementary Fig. 3b) . Although immunostaining showed that MM cells also expressed CyPA (Fig. 4h and Supplementary Fig. 3c ), they secreted it at very low levels compared with BMECs (Supplementary Fig. 3d) HSPE1  FABP5  HN1  MIF   CCFL1  GLO1  PFN1  ARHGDIB  TXN LAALS  MTPN  RPLP2  STMN1   PSMA3   LZIC   PTMS   CFL1   ACP1   SOD1   APCS  BASP1   CAPNS1  CLIC1  YWHAZ  GSTO1  GSTM4  MYL6  PARK7  PEA15  PGLS  PRDX2  TXNDC17  TAGLN  TPT1 LGALS1 PRDX6 P T 2 P T 3 P T 4 P T 5 P T 6 P T 7 P T 8 P T 9 P T 1 0 P T 1 1 P T 1 2 P T 1 P T 2 P T 3 P T 4 P T 5 P T 6 P T 7 P T 8 P T 9 P T 1 0 P T 1 1 P T 1 2 CyPB concentration (ng ml . ELISA was done once and in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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In addition, immunostaining showed much lower CyPA expression in endothelial cells from other tissues than in those from bone marrow ( Supplementary Fig. 4) . Next, we measured serum levels of eCyPA and eCyPB in subjects with MM whose bone marrow and peripheral blood were collected at the time of diagnosis. As documented by ELISA, eCyPA was more abundant in bone marrow serum than in peripheral blood serum (bone marrow, 10.54 ± 10.72 ng ml −1 ; peripheral blood, 1.59 ± 0.94 ng ml −1 ) (Fig. 4i) . In the same samples, serum levels of eCyPB were much lower than those of eCyPA, with no major differences detected between bone marrow and peripheral blood (Fig. 4j) . eCyPA levels in peripheral blood serum were higher in subjects with MM than in those with MGUS ( Supplementary Fig. 4b ), indicating that this parameter could be a marker of disease progression.
eCyPA promotes the proliferation and colonization of MM cells Because of the documented role of eCyPA in neutrophil migration 27 , it was of interest to evaluate the role of eCyPA in MM cell migration in vitro and in vivo.
eCyPA promoted the migration of MM cells in vitro in a timeand concentration-dependent manner (Fig. 5a) . Although maximal responses were observed at 50 ng ml −1 , migration was induced at eCyPA concentrations typically found in the bone marrow serum of MM subjects (Fig. 4i) . eCyPA also induced migration of various MM cell lines (Supplementary Fig. 4c ) and primary MM cells ( Supplementary Fig. 4d) ; there was no major difference in the migration of primary MM cells incubated with BMEC-60 cells as compared to 50 ng ml −1 eCyPA. The promotion of MM cell migration by bone marrow serum from MM patients varied with eCyPA level (Supplementary Fig. 4e) , and no major differences in migration were observed between cells treated with 50 ng ml −1 of eCyPA and cells treated with the same concentration of eCyPB (Supplementary Fig. 5a ). MM cell migration was decreased when BMEC-60 (Fig. 5b) or BMEC-1 cells (Supplementary Fig. 5b-d) were transduced with CyPA shRNA (Supplementary Fig. 5b ). As would be expected from an on-target effect of eCyPA shRNA, the addition of eCyPA restored migration of MM cells cultured with BMEC-1 cells transduced with CyPA shRNA (Supplementary Fig. 5d ). Treatment of MM cells with eCyPA activated several signaling pathways in MM cells and increased the level of the more highly glycosylated form of CD147 that induces matrix metalloprotease production and promotes metastasis 26, 27 ( Fig. 5c) . eCyPA increased CD147 expression in a concentration-and time-dependent manner (Supplementary Fig. 5e ) and increased the expression of matrix metalloprotease 9 (MMP-9) (Fig. 5c) . The effects on signaling in MM cells induced by culture with BMEC-60 cells were reversed by CyPA knockdown in the BMEC-60 cells ( Supplementary  Fig. 5f ). eCyPA also enhanced the proliferation of MM cells in a concentration-dependent manner (Supplementary Fig. 5g) .
The migration and proliferation of MM.1S-luc cells in scaffolds was inhibited when the scaffolds were coated with BMEC-60 cells that had been transduced with CyPA shRNA (Fig. 5d-f) . Immunostaining confirmed uniform coating of scaffolds with both BMEC-60 cells transduced with control shRNA and BMEC-60 cells transduced with CyPA shRNA (Fig. 5f) . These results were replicated in two other experiments (Supplementary Fig. 6a ) and in experiments in which the migration and proliferation of H929-luc cells were tested in scaffolds coated with BMEC-60 cells (Supplementary Fig. 6b-d) . One representative pair of mice is shown. Scale bars in i, 100 µm. Statistical analyses of tumor burden were done using factorial analysis in SPSS 13.0. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. npg eCyPA promotes the migration and proliferation of MM through CD147 Because CD147 is the principal receptor mediating chemotaxis by eCyPA [26] [27] [28] , we evaluated CD147 expression in MM cells. Flow cytometry and immunostaining showed that most MM cell lines, including MM.1S-luc cells (Supplementary Fig. 7a ) and primary tumor samples ( Supplementary Fig. 7b ), expressed CD147. At the mRNA level, CD147 was present in most MM samples, with higher levels detected in MM samples than in normal plasma cells (Supplementary Fig. 7c ), indicating that CD147 could be a marker of disease progression. Next, we evaluated whether inactivation of CD147 on MM cells could block the action of eCyPA in vitro and in vivo. MM cells transduced with CD147 shRNA (Supplementary Fig. 7d) showed decreased migration when cultured with BMEC-60 cells or when treated with eCyPA ( Supplementary Fig. 7e,f) . The signaling changes induced by eCyPA in MM cells (Fig. 5c) were reversed when the cells were transduced with CD147 shRNA (Supplementary Fig. 7g ). Using the scaffold xenograft mouse model, we observed that knockdown of CD147 in MM.1S-luc cells inhibited their migration and proliferation within scaffolds coated with BMEC-60 cells (Fig. 5g-i) .
Targeting the eCyPA-CD147 complex for MM therapy To test targeting of the eCyPA-CD147 complex as a potential strategy for MM therapy, we first evaluated whether an antibody to CD147 known to inhibit neutrophil migration in a mouse model of inflammation 29 also inhibits the migration of MM cells. In a concentration-dependent manner, treatment with anti-CD147 reduced eCyPA-induced migration of MM.1S-luc cells ( Supplementary  Fig. 7h) ; reduced levels of pERK, pSTAT3 and pAKT; and increased levels of cleaved poly-(adenosine diphosphate ribose) polymerase (PARP) (Supplementary Fig. 8a,b ). An antibody to CXCR4 (ref. 12) did not inhibit CyPA-induced migration of MM.1S-luc cells (Supplementary Fig. 8c) . Migration of MM.1S-luc cells was also reduced by anti-CD147 when cells were cultured with primary BMECs, but not when they were cultured with primary BMSCs isolated from the same person (Supplementary Fig. 8d ). Treatment with anti-CXCR4 did not inhibit the migration of MM.1S-luc cells induced by primary BMECs, but it did inhibit migration induced by primary BMSCs (Supplementary Fig. 8d ). We then used ELISA to evaluate the secretion of eCyPA and SDF-1. As shown in Supplementary Figure 8e , eCyPA was detected in conditioned medium from primary BMECs but not in that from primary BMSCs, and the opposite was observed for SDF-1.
The documented role of the STAT3 pathway in promoting the survival of MM cells, as well as our observations of decreased pSTAT3 levels in MM cells transduced with CD147 shRNA or treated with anti-CD147 and of increased levels of cleaved PARP in MM cells treated with anti-CD147, prompted us to evaluate whether anti-CD147 could have therapeutic effects in the in vivo scaffold model. Local injection of anti-CD147, but not of isotype control antibody, reduced tumor burden in mice implanted with scaffolds precoated with BMEC-60 cells and MM.1S-luc cells (Fig. 6a,b and Supplementary Fig. 9a ). MM.1S-luc cells in scaffolds of mice treated with anti-CD147 showed an increased amount of immunostaining for cleaved caspase 3 compared with those in mice treated with isotype antibody (Supplementary Fig. 9a) . Analysis of immune-mediated activity revealed that complement-dependent cytotoxicity was not induced by anti-CD147 (Supplementary Fig. 9b ). As expected given the specificity of the anti-CD147 for human CD147, no side effects were observed in host mouse tissues (data not shown). npg Decreased CD147 expression in circulating MM cells We next evaluated CD147 expression in plasma cells from the lymph nodes and bone marrow of healthy subjects, as well as in plasma cells from the bone marrow and peripheral blood of subjects with MM. Because of the paucity of plasma cells in the peripheral blood of MM subjects 7 , CD147 expression was determined by immunofluorescence on cytospin preparations using CD138 as a plasma-cell marker 30 . Ten of ten bone marrow plasma cells from each of two MM subjects (cases 1 and 2) expressed high levels of CD147, whereas nine of ten peripheral blood plasma cells from each of the same individuals expressed CD147 only at low levels ( Fig. 6c and Supplementary Fig. 9c ). In contrast, nine of ten bone marrow plasma cells from each of two healthy subjects (cases 3 and 5) and eight of ten lymph node plasma cells from each of two other healthy subjects (cases 4 and 6) expressed CD147 only at low or undetectable levels ( Fig. 6c and Supplementary Fig. 9d ).
CLL and LPL cells express CD147 and migrate in response to eCyPA As CLL and LPL cells, like MM cells, preferentially colonize the bone marrow 4 , it was of interest to examine whether CLL and LPL cells express CD147 and whether eCyPA has chemotactic effects on these cells. Immunostaining and flow cytometry showed that a high percentage of CLL and LPL primary cells from ten different subjects expressed CD147 ( Supplementary Fig. 10a,b) . Moreover, flow cytometry showed that the CLL cell line HG3 and freshly isolated cells from a primary CLL tumor (CLLPT-1 cells), as well as the LPL cell line BCWM.1 and freshly isolated cells from an LPL primary tumor (LPLPT-1 cells) ( Supplementary Fig. 10c,d) , expressed high levels of CD147. In migration assays, both BMEC-60-derived conditioned medium and eCyPA treatment enhanced the migration of HG3, CLLPT-1, BCWM.1 and LPLPT-1 cells (Supplementary Fig. 10e,f) .
DISCUSSION
The mechanisms responsible for the preferential colonization of MM and certain other B cell malignancies in the bone marrow are not entirely known 6, 31 . Similar to observations regarding HSC homing to the bone marrow 6, 7 , the CXCR4-SDF-1 axis has been shown to have an important role in the migration and bone marrow homing of MM cells 12 . However, the specific cell type that secretes SDF-1 in the bone marrow is not known 12 . Here we offer evidence of a previously unknown molecular basis for the migration and bone marrow colonization of MM cells. We found that eCyPA is secreted by BMECs, but not by endothelial cells from other vascular beds or other subtypes of stromal cells in the bone marrow, and that eCyPA acts as a signaling factor to promote the migration and proliferation of MM cells via binding to its cognate receptor, CD147, on MM cells. These studies identify eCyPA as a new target of the β-catenin-BCL9 complex and provide evidence for functional roles of the Wnt pathway and of BMECs in MM pathogenesis. Furthermore, we identified BMECs as the main source of eCyPA, but not of SDF-1, which is secreted by BMSCs. To our knowledge, this is the first suggestion that BMECs and BMSCs have different roles in the pathogenesis of MM. Although CyPA was initially recognized as the intracellular target of the immunosuppressive drug cyclosporine A, recent studies showed that cells can secrete eCyPA in response to inflammatory stimuli 25, 26 . eCyPA can initiate a signaling response in target cells and is a potent chemoattractant [25] [26] [27] . Studies aimed at establishing the mechanism whereby eCyPA promotes chemotaxis have identified CD147, also known as extracellular matrix metalloproteinase inducer, as its principal receptor 27, 32 .
CD147 has critical roles in intercellular communication involved in chronic inflammation, tumor metastasis and angiogenesis 28, 32 .
Via cell-cell and cell-matrix interactions, CD147 induces expression of the matrix metallopeptidases required for tumor invasion and metastasis 28 . Recently, the expression of CD147 has been broadly correlated with the progression of various carcinomas, as well as hematological malignancies such as MM 33, 34 . With regard to MM, it was documented that eCyPB induces the proliferation of MM cells 33 , although the concentrations tested were much higher than those in the bone marrow serum of MM subjects. Relevant to our studies is the observation that CD147 expression increases with disease progression in MM cells, but that CD147 is not expressed in plasma cells from healthy individuals, the counterpart to neoplastic MM cells 33 .
On the basis of the present findings and the generally recognized trafficking model of normal lymphocytes and of HSC recruitment to the bone marrow 6,7 , we propose a mechanism that could explain both preferential bone marrow colonization by MM cells during early-stage disease and the loss of preferential homing during late-stage disease (Fig. 6d) . According to this model, eCyPA acts as a chemoattractant to promote the migration of MM cells, which express CD147, along an eCyPA concentration gradient between the peripheral blood and blood marrow, whereas normal plasma cells do not accumulate in the bone marrow because they do not express CD147. The eCyPA gradient is generated because endothelial cells from the bone marrow, but not those from other sites, produce and secrete eCyPA in high amounts. In addition, bone marrow myeloid cells produce and secrete eCyPA. Although MM cells also express CyPA, they secrete it at very low rates relative to BMECs, suggesting that MM cells are less efficient at Rho kinase-mediated CyPA secretion 35 than are BMECs. Therefore, we suggest that MM-derived eCyPA is unlikely to have a significant role in MM recruitment to the bone marrow, at least during early-stage disease, when the tumor burden is low. As MM cells circulate in the peripheral blood and encounter progressively higher concentrations of eCyPA, binding of eCyPA to CD147 will further increase CD147 expression by MM cells, thereby enhancing their migration. Additionally, extravasation of MM cells, required for penetration through the subendothelial basement membrane, is mediated by proteolytic enzymes such as MMP-9, the level of which rises upon eCyPA engagement of CD147 (ref. 28) . Once MM cells enter the bone marrow, colonization is further enhanced by the direct exocrine action of eCyPA and by local production and secretion of other growth factors and chemokines (for example, Laminin-1, SDF-1 and vascular endothelial growth factor) 6, 7 .
According to the proposed model, eCyPA promotes the preferential migration of MM cells from the blood to the bone marrow, followed by the selective survival and proliferation of the cells within the bone marrow. eCyPA in the bone marrow might also serve as a 'retention signal' for MM cells, a possibility that needs to be further investigated. During disease progression, genetic and epigenetic changes in MM cells that decrease CD147 expression could enable the cells to leave the bone marrow and colonize extramedullary sites.
Thus, in addition to other mechanisms implicated in the homing of lymphoid cells 31 , the CyPA-CD147 axis might also have an important role. On the basis of our data, we propose that the eCyPA-CD147 complex is an attractive target for therapeutic intervention in MM. Agents that could potentially disrupt this interaction can be grouped into those that directly target CD147, eCyPA or their interaction 27 and those that act indirectly via inhibition of the Wnt-β-catenin-BCL9 complex 17 . Using an antibody to CD147 that blocks eCyPA-and BMEC-induced migration of MM cells, we obtained evidence that inhibition of the eCyPA-CD147 complex is associated with anti-MM activity. This approach might also be useful for treating CLL and LPL, as these tumor types also express CD147 and migrate in response to eCyPA. Notably, npg CD147 inhibition using an antibody to CD147 was found to be of therapeutic benefit in a rabbit model of hepatocellular carcinoma 36 .
Although our studies indicate that targeting the CyPA-CD147 complex could be therapeutic for MM, additional preclinical studies, including with other mouse models of MM, will be needed to further validate this hypothesis. In addition, because of the broad tissue pattern of CD147 expression, unintended side effects should be carefully and systematically evaluated. Because the anti-CD147 used in our studies was specific to human CD147, such unwanted side effects on CD147-positive normal mouse tissue could not be assessed.
In summary, our studies have uncovered a pivotal role of the eCyPA-CD147 axis in the functional interaction between MM cells and BMECs and have established a functional link between the Wnt-β-catenin-BCL9 pathway and the eCyPA-CD147 system, suggesting a role for chronic inflammation in MM pathogenesis. The translational extension of these studies into the clinical setting could include the identification of biomarkers of disease progression within the downstream signaling cascade triggered by eCyPA-CD147 binding, as well as the development of therapies targeting the eCyPA-CD147 interaction in MM and other B cell malignancies that preferentially colonize the bone marrow.
METHODS
Methods and any associated references are available in the online version of the paper. 
